Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Kaplan

Showing results (71-80 of 142) with videos related to

Pageof 15
Sort By:
AIDS (London, England)|March 4, 2026
Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trialPhyo Pyae Nyein, Mark W Donoghoe, Nnakelu Eriobu, et al.
Ophthalmology. Retina|April 2, 2019
Pneumatic Retinopexy Experience and Outcomes of Vitreoretinal Fellows in the United States: A Multicenter StudyParisa Emami-Naeini, Jordan Deaner, Ferhina Ali, et al.
JAMA|June 12, 2003
Incremental treatment costs in national cancer institute-sponsored clinical trialsDana P Goldman, Sandra H Berry, Mary S McCabe, et al.
The Lancet. Oncology|April 8, 2014
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trialHarpreet Wasan, Angela M Meade, Richard Adams, et al.
British Journal of Cancer|June 29, 2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumabCong Zhou, Andrew Clamp, Alison Backen, et al.
Kidney Cancer (Clifton, Va.)|February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.
International Journal of Cancer|April 25, 2022
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndromeKatie Watts, Christopher Wills, Ayman Madi, et al.
Open Forum Infectious Diseases|July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled AnalysisStefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
The Lancet. Gastroenterology & Hepatology|December 20, 2017
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trialRichard Adams, Ewan Brown, Louise Brown, et al.
Human Mutation|April 16, 2013
Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancerChristopher G Smith, Marc Naven, Rebecca Harris, et al.
Pageof 15

Showing results (71-80 of 142) with videos related to

Sort By:
Pageof 15
AIDS (London, England)|March 4, 2026
Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trialPhyo Pyae Nyein, Mark W Donoghoe, Nnakelu Eriobu, et al.
Ophthalmology. Retina|April 2, 2019
Pneumatic Retinopexy Experience and Outcomes of Vitreoretinal Fellows in the United States: A Multicenter StudyParisa Emami-Naeini, Jordan Deaner, Ferhina Ali, et al.
JAMA|June 12, 2003
Incremental treatment costs in national cancer institute-sponsored clinical trialsDana P Goldman, Sandra H Berry, Mary S McCabe, et al.
The Lancet. Oncology|April 8, 2014
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trialHarpreet Wasan, Angela M Meade, Richard Adams, et al.
British Journal of Cancer|June 29, 2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumabCong Zhou, Andrew Clamp, Alison Backen, et al.
Kidney Cancer (Clifton, Va.)|February 12, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.
International Journal of Cancer|April 25, 2022
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndromeKatie Watts, Christopher Wills, Ayman Madi, et al.
Open Forum Infectious Diseases|July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled AnalysisStefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
The Lancet. Gastroenterology & Hepatology|December 20, 2017
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trialRichard Adams, Ewan Brown, Louise Brown, et al.
Human Mutation|April 16, 2013
Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancerChristopher G Smith, Marc Naven, Rebecca Harris, et al.
Pageof 15